Targeting 4-1BB and PD-L1 induces potent and durable antitumor immunity in B-cell lymphoma

Targeting 4-1BB and PD-L1 induces potent and durable antitumor immunity in B-cell lymphoma

IntroductionAlthough PD-1/L1 mAb has demonstrated clinical benefits in certain cancer types, low response rate and resistance remain the main challenges for the application of these immune checkpoint inhibitors (ICIs). 4-1BB is a co-stimulator molecule expressed in T cells, which could enhance T cel...

Full description

Bibliographic Details
Main Authors: Yichen Wang, Xuyao Zhang, Caili Xu, Yanyang Nan, Jiajun Fan, Xian Zeng, Byoung S. Kwon, Dianwen Ju
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Immunology
Subjects:
B-cell lymphoma
anti-PD-L1 ICI
4-1BB agonist
CD8+ T cells
combination therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.1004475/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.1004475/full

Similar Items